UBS Group
JUNO

UBS Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

UBS Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-68,425
Closed -$3.13M – 8501
2017
Q4 		$3.13M Sell
68,425
-59,355
-46% -$2.96M ﹤0.01% 2803
2017
Q3 		$5.73M Sell
127,780
-39,916
-24% -$1.36M ﹤0.01% 2085
2017
Q2 		$5.01M Buy
167,696
+98,683
+143% +$2.44M ﹤0.01% 2148
2017
Q1 		$1.53M Sell
69,013
-119,011
-63% -$2.55M ﹤0.01% 3173
2016
Q4 		$3.54M Buy
188,024
+30,452
+19% +$745K ﹤0.01% 2391
2016
Q3 		$4.73M Buy
157,572
+66,851
+74% +$2.08M ﹤0.01% 2070
2016
Q2 		$3.49M Buy
90,721
+52,957
+140% +$2.2M ﹤0.01% 2296
2016
Q1 		$1.44M Sell
37,764
-95,515
-72% -$3.33M ﹤0.01% 2962
2015
Q4 		$5.86M Buy
133,279
+49,439
+59% +$2.45M ﹤0.01% 1824
2015
Q3 		$3.41M Buy
83,840
+73,668
+724% +$3.23M ﹤0.01% 2260
2015
Q2 		$543K Sell
10,172
-124,511
-92% -$6.61M ﹤0.01% 4054
2015
Q1 		$8.17M Buy
134,683
+38,071
+39% +$1.85M 0.01% 1631
2014
Q4 		$5.04M Buy
+96,612
New +$4.32M ﹤0.01% 2081

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS Group's JUNO Position: Q1 2018 in Review

UBS Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 68,425 shares — an estimated $3.13M sold.

UBS Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $8.17M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • UBS Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 68,425 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.13M.
  • UBS Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • UBS Group's Juno Therapeutics, Inc. position peaked at $8.17M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.